PLX vs. SCHG
Compare and contrast key facts about Protalix BioTherapeutics, Inc. (PLX) and Schwab U.S. Large-Cap Growth ETF (SCHG).
SCHG is a passively managed fund by Charles Schwab that tracks the performance of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. It was launched on Dec 11, 2009.
Performance
PLX vs. SCHG - Performance Comparison
Loading graphics...
PLX vs. SCHG - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
PLX Protalix BioTherapeutics, Inc. | 20.56% | -4.26% | 5.62% | 29.93% | 64.72% | -77.09% | 10.67% | 5.47% | -52.96% | 48.58% |
SCHG Schwab U.S. Large-Cap Growth ETF | -10.59% | 17.50% | 34.95% | 50.10% | -31.80% | 28.11% | 39.14% | 36.02% | -1.36% | 28.05% |
Returns By Period
In the year-to-date period, PLX achieves a 20.56% return, which is significantly higher than SCHG's -10.59% return. Over the past 10 years, PLX has underperformed SCHG with an annualized return of -12.66%, while SCHG has yielded a comparatively higher 16.83% annualized return.
PLX
- 1D
- 3.83%
- 1M
- -24.65%
- YTD
- 20.56%
- 6M
- -2.25%
- 1Y
- -15.23%
- 3Y*
- 1.10%
- 5Y*
- -13.53%
- 10Y*
- -12.66%
SCHG
- 1D
- 3.67%
- 1M
- -5.12%
- YTD
- -10.59%
- 6M
- -8.51%
- 1Y
- 16.81%
- 3Y*
- 21.91%
- 5Y*
- 12.55%
- 10Y*
- 16.83%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
PLX vs. SCHG — Risk / Return Rank
PLX
SCHG
PLX vs. SCHG - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Protalix BioTherapeutics, Inc. (PLX) and Schwab U.S. Large-Cap Growth ETF (SCHG). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| PLX | SCHG | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | -0.19 | 0.75 | -0.94 |
Sortino ratioReturn per unit of downside risk | 0.33 | 1.23 | -0.91 |
Omega ratioGain probability vs. loss probability | 1.05 | 1.17 | -0.12 |
Calmar ratioReturn relative to maximum drawdown | -0.28 | 1.03 | -1.31 |
Martin ratioReturn relative to average drawdown | -0.43 | 3.54 | -3.97 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| PLX | SCHG | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | -0.19 | 0.75 | -0.94 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.19 | 0.57 | -0.76 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | -0.16 | 0.79 | -0.95 |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.06 | 0.79 | -0.85 |
Correlation
The correlation between PLX and SCHG is 0.20, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Dividends
PLX vs. SCHG - Dividend Comparison
PLX has not paid dividends to shareholders, while SCHG's dividend yield for the trailing twelve months is around 0.43%.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
PLX Protalix BioTherapeutics, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
SCHG Schwab U.S. Large-Cap Growth ETF | 0.43% | 0.36% | 0.39% | 0.46% | 0.55% | 0.42% | 0.52% | 0.82% | 1.27% | 1.01% | 1.04% | 1.22% |
Drawdowns
PLX vs. SCHG - Drawdown Comparison
The maximum PLX drawdown since its inception was -99.91%, which is greater than SCHG's maximum drawdown of -34.59%. Use the drawdown chart below to compare losses from any high point for PLX and SCHG.
Loading graphics...
Drawdown Indicators
| PLX | SCHG | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.91% | -34.59% | -65.32% |
Max Drawdown (1Y)Largest decline over 1 year | -56.03% | -16.41% | -39.62% |
Max Drawdown (5Y)Largest decline over 5 years | -86.98% | -34.59% | -52.39% |
Max Drawdown (10Y)Largest decline over 10 years | -94.38% | -34.59% | -59.79% |
Current DrawdownCurrent decline from peak | -99.75% | -13.34% | -86.41% |
Average DrawdownAverage peak-to-trough decline | -93.62% | -5.22% | -88.40% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 36.94% | 4.78% | +32.16% |
Volatility
PLX vs. SCHG - Volatility Comparison
Protalix BioTherapeutics, Inc. (PLX) has a higher volatility of 28.27% compared to Schwab U.S. Large-Cap Growth ETF (SCHG) at 6.67%. This indicates that PLX's price experiences larger fluctuations and is considered to be riskier than SCHG based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| PLX | SCHG | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 28.27% | 6.67% | +21.60% |
Volatility (6M)Calculated over the trailing 6-month period | 56.55% | 12.51% | +44.04% |
Volatility (1Y)Calculated over the trailing 1-year period | 82.31% | 22.43% | +59.88% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 70.83% | 22.32% | +48.51% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 79.30% | 21.51% | +57.79% |